Tirzepatide

Tirzepatide is FDA-approved for treating type 2 diabetes by mimicking GLP-1 and GIP hormones to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and lower blood sugar levels, often achieving significant reductions in HbA1c.¹,²,³,⁴ It is also approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions, promoting substantial weight loss through appetite suppression and reduced food intake, with clinical trials showing up to 20-21% body weight reduction over 72 weeks.²,³,⁵ Additional evidence indicates improvements in cardiovascular risk factors, liver fat reduction, and potential benefits in conditions like obstructive sleep apnea via weight loss and anti-inflammatory effects, though some uses remain investigational.¹,²,⁶

Tirzepatide, a dual GLP-1/GIP receptor agonist used as an active pharmaceutical ingredient in approved injectable medicines for type 2 diabetes and chronic weight management, commonly causes gastrointestinal side effects such as nausea, vomiting, diarrhea, stomach pain, constipation, decreased appetite, heartburn, burping, and flatulence, which are most frequent at treatment initiation or dose escalation and often improve over time.³,⁷,⁸ Less common side effects include fatigue, headaches, dizziness, injection site reactions, taste changes, and mild increases in heart rate or liver enzymes.⁷,⁸ Serious safety considerations encompass risks of pancreatitis (severe abdominal pain radiating to the back), gallbladder disease (including gallstones), acute kidney injury from dehydration due to vomiting or diarrhea, severe allergic reactions (swelling, rash, breathing difficulty), low blood sugar (hypoglycemia), thyroid C-cell tumors, and rare reports of tachycardia, vision changes, or bowel obstruction; patients should seek immediate medical attention for these and undergo regular monitoring of kidney function, blood sugar, and thyroid symptoms.³,⁴,⁷,⁸,⁹ To mitigate risks, start at low doses with gradual increases, stay hydrated, eat smaller meals, and avoid use in patients with personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.³,⁹

Tirzepatide is a synthetic polypeptide that acts as a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.¹⁰,¹¹,¹² It mimics these gut hormones to stimulate glucose-dependent insulin secretion from pancreatic beta cells, suppress glucagon release from alpha cells, and delay gastric emptying, thereby lowering blood glucose levels in type 2 diabetes.²,¹⁰,¹¹ Tirzepatide also acts on brain regions to reduce appetite and food intake, promoting significant weight loss, and increases insulin sensitivity and adiponectin levels.²,¹⁰,¹² Administered as a once-weekly subcutaneous injection, its prolonged half-life results from albumin binding via a C20 fatty diacid moiety.¹¹,¹² It is approved for type 2 diabetes (as Mounjaro) and chronic weight management (as Zepbound).²,¹²